EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation

DURAVYU™ in NPDR

PAVIA Phase 2 Clinical Trial

Topline Results

May 6, 2024

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	DURAVYU™ has been conditionally accepted by the FDA as the proprietary name
for EYP-1901. DURAVYU is an investigational product; it has not been approved by

the FDA. FDA approval and the timeline for potential approval is uncertain.

Legal Disclaimers

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about the sufficiency of our existing cash resources through topline data for Phase 3 clinical trials for DURAVYU™ in wet AMD; our expectations regarding the timing and clinical development of our product candidates, including DURAVYU and EYP-2301; the potential for DURAVYU as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward- looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to access needed capital; termination or breach of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of guidelines, recommendations and studies; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward- looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

2 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Committed to

developing

therapeutics to

improve the lives of patients with serious retinal diseases

3 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Pipeline represents potential multi billion-dollar opportunities using our bioerodible Durasert E™ IVT delivery technology

• DURAVYU™ (vorolanib intravitreal insert) - vorolanib, a selective and patented TKI in Durasert E™
• • Positive topline Phase 2 data in wet AMD
  • First Phase 3 trial in wet AMD planned to initiate in 2H 2024
  • Topline Phase 2 data in NPDR; 12-month data expected in 3Q 2024
  • Topline Phase 2 data in DME anticipated in Q1 2025
• EYP-2301- razuprotafib, a patented TIE-2 agonist for serious retinal diseases in Durasert E™

Durasert® - proven, safe IVT drug delivery technology

• Bioerodible Durasert E™ and non-erodible formulations
• Safely administered to thousands of patient eyes across four FDA approved products with non-erodible formulations

Strong Balance Sheet

• $331M of cash and investments on December 31, 2023
• Cash runway through Phase 3 wet AMD pivotal trials topline data in

2026

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

IVT, intravitreal injection

Potential Multi Billion-Dollar Product Opportunities Leveraging Innovative Drug Delivery Technology, Bioerodible Durasert E™

Durasert E™ Programs	Indication	Discovery	Pre-Clin	Phase 1	Phase 2	Phase 3	Next Milestone
	Wet AMD	single-dose,6-month maintenance therapy		First pivotal Phase
		3 2H 2024
DURAVYU (EYP-1901) -
vorolanib in Durasert E™	NPDR		single-dose,9-month treatment			12-month data 3Q
(tyrosine kinase inhibitor)				2024
	DME	single-dose,6-month treatment			Topline data in
			Q1 2025
EYP-2301 - razuprotafib in	serious retinal						Pre-clin tox and PK
Durasert E™
diseases						data
(TIE-2 agonist)
Complement inhibition	GA						Potential product
					candidate in 2024

	non-clinical	trial underway
4	©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	wet AMD, wet age-related macular degeneration; EOP2, End of Phase 2; FPI, first patient in; NPDR, non-proliferative diabetic retinopathy; D

Vorolanib Brings a Potential New MOA to the Treatment of VEGF- Mediated Retinal Diseases by Inhibiting all Isoforms of VEGF and PDGF

• Potent and selective pan-VEGF receptor inhibition
• Composition of matter patent into 2037
• Demonstrated neuroprotection in a validated retinal detachment animal model
• Inhibits PDGF which may lead to antifibrotic benefit
• Reduced off-target binding - does not inhibit TIE-2 at clinically relevant doses

		SoC, standard of care; ANG, angiopoietin; PDGF(R), platelet-derived growth factor
5	©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	(receptor); PLGF, placental growth factor; TIE-2,tyrosine-protein kinase receptor
		TIE-2; VEGF(R), vascular endothelial growth factor (receptor).

DURAVYU: VEGF Receptor Binding Vorolanib In Bioerodible Durasert E™

Insert is ~1/5000 of vitreous volume

6 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

• Positive efficacy data in wet AMD from Phase 1 DAVIO and Phase 2 DAVIO 2 clinical trials
• Favorable safety profile with no ocular or systemic DURAVYU-related SAEs reported in ongoing Phase 2 clinical trials
• Immediately bioavailable featuring an initial burst of drug followed by zero order kinetics release for ~9 months
• Vorolanib fully eluted prior to complete bioerosion of the matrix to control release and allow redosing regimen
• Delivered in the physician office via routine intravitreal injection
• Shipped and stored at ambient temperature

VEGF - vascular endothelial growth factor: AMD - age related macular degeneration;

Phase 2 PAVIA Clinical Trial Topline Results

A RANDOMIZED, MULTICENTER TRIAL VERSUS SHAM CONTROL

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

The PAVIA Clinical

Trial in NPDR

A clinical trial evaluating two doses of DURAVYU against a sham control as a 9- month therapy

Design:

Multi-center, randomized, double-masked, single injection of DURAVYU compared to sham control in patients with moderately-severe to severe NPDR without active CI-DME

Primary outcome:

Percentage of patients with a ≥2 step DRSS improvement score at week 36 (9 months) as evaluated by an independent reading center

Key secondary endpoints:

• Reduction in vision-threatening complications
• CI-DMEoccurrence
• Safety

8	©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	NPDR, non-proliferative diabetic retinopathy; CI-DME,central-involved diabetic macular
edema; DRSS, diabetic retinopathy severity scale; DME, diabetic macular edema

Phase 2 PAVIA is a Randomized, Double-Masked, Single Injection of DURAVYU Compared to Sham Control

-D21 to -D5	D1	W4	W12	W24	W36	W48
DURAVYU
2mg low dose
n=26
DURAVYU
3mg high dose
n=25
Control Sham
n=26
	R A N D O M I Z A T I O N

D U R A V Y U

1 ⁰ E N D P O I N T U N M A S K D A T A

DURAVYU DOSING VISIT SCHEDULED	SHAM INJECTION
9 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

PAVIA Baseline Characteristics Balanced Across Arms

			Control Sham		DURAVYU 2mg	DURAVYU 3mg
			(n=26)		(n=26)	(n=25)
	Mean age, years (range)		56.9 (29-83)		56.8 (24-73)	60.2 (34-81)
	Female, %		50.0		46.2	36.0
	DRSS score, %		53.8		65.4	56.0
	Moderately-severe NPDR (score of 47)
		46.2		34.6	44.0
	Severe NPDR (score of 53)
	Mean BCVA, ETDRS letters (range)		81.3 (69-90)		83.2 (68-90)	81.8 (67-95)
	Mean CST, μm (range)		273.9 (199-329)		265.8 (193-319)	282.7 (201-325)
	Median duration of diabetes (DM), years		14.5 (0.3-29.1)		13.8 (0.3-46.3)	15.9 (0.3-42.3)
	(range)
		PRELIMINARY DATA - PENDING FINAL ANALYSIS
		DRSS, diabetic retinopathy severity scale; NPDR, non-proliferative diabetic retinopathy; BCVA, best corrected visual
10 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	acuity; ETDRS, early treatment diabetic retinopathy study; CST, central subfield thickness; DM, diabetes mellitus